<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521881</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KEP-456</org_study_id>
    <secondary_id>2020-003391-40</secondary_id>
    <nct_id>NCT04521881</nct_id>
  </id_info>
  <brief_title>Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults</brief_title>
  <acronym>CRASH-4</acronym>
  <official_title>Intramuscular Tranexamic Acid for the Treatment of Symptomatic Mild Traumatic Brain Injury in Older Adults: a Randomised, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid (TXA) reduces head injury deaths. The CRASH-4 trial aims to assess the&#xD;
      effects of early intramuscular TXA on intracranial haemorrhage, disability, death, and&#xD;
      dementia in older adults with symptomatic mild head injury&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TXA reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots. Results&#xD;
      from randomised trials (CRASH-3 and NCT01990768) show that early treatment with TXA (given&#xD;
      intravenously) reduces head injury deaths (pooled RR 0.89, 95% CI 0.80-0.99). In the CRASH-3&#xD;
      trial, the reduction in head injury deaths with TXA was largest in patients with mild and&#xD;
      moderate head injuries, particularly if patients were treated soon after injury. However, the&#xD;
      CRASH-3 trial included mild TBI patients only if they had intracranial bleeding on CT scan.&#xD;
      It is uncertain whether the results apply to mild TBI patients more generally. CRASH-4 is a&#xD;
      randomised, double blind, placebo-controlled trial in symptomatic mild TBI in about 10,000&#xD;
      older adults. The pilot phase will include about 500 patients. The trial aims to provide&#xD;
      reliable evidence about the effects of early intramuscular TXA on intracranial haemorrhage,&#xD;
      disability, death, and dementia in older adults with symptomatic mild head injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomised, double blind, placebo controlled trial among 10,000 older adults with mild traumatic brain injury.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking will be done by an independent clinical trials supply company. It will involve the removal of the original manufacturer's label and replacement with the clinical trial label bearing the randomisation number, which will be used as the pack identification. Apart from the randomisation number, all pack label texts will be identical for tranexamic acid and placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Emergency department discharge</measure>
    <time_frame>within 24 hours</time_frame>
    <description>discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial bleeding on CT scan</measure>
    <time_frame>within 48 hours</time_frame>
    <description>any bleeding on the last scan conducted within 48 hours of randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head injury related death</measure>
    <time_frame>within 48 hours</time_frame>
    <description>In-hospital head injury-related death within 48 hours of injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>within 28 days</time_frame>
    <description>Cause of death will be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>within 28 days</time_frame>
    <description>The Barthel scale will be used to assess functional disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of ability to self-care</measure>
    <time_frame>within 28 days</time_frame>
    <description>Scale of 1 to 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurosurgery</measure>
    <time_frame>within 28 days</time_frame>
    <description>receipt of neurosurgery and type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in ICU</measure>
    <time_frame>within 28 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission to hospital</measure>
    <time_frame>within 28 days</time_frame>
    <description>readmission after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular occlusive events</measure>
    <time_frame>within 28 days</time_frame>
    <description>pulmonary embolism, myocardial infarction, deep vein thrombosis and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intramuscular injection site reaction</measure>
    <time_frame>within 28 days</time_frame>
    <description>frequency and type of reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>within 28 days</time_frame>
    <description>Any untoward medical occurrence (other than pre-specified outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dementia</measure>
    <time_frame>1 year</time_frame>
    <description>The occurrence of all-cause dementia will be determined 12 months after randomisation. Dementia will be identified through linkage to routinely collected health-care data.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of Tranexamic acid 500mg given by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 500 MG</intervention_name>
    <description>given once as an intramuscular injection</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50 years or older (actual or estimated)&#xD;
&#xD;
          -  History or evidence of head injury (e.g. laceration, bruise, swelling or pain in head&#xD;
             or face)&#xD;
&#xD;
          -  GCS â‰¥ 13&#xD;
&#xD;
          -  Has one or more of the following:&#xD;
&#xD;
               1. has or had any impaired consciousness (loss of consciousness, amnesia, or&#xD;
                  confusion)&#xD;
&#xD;
               2. nausea or vomiting&#xD;
&#xD;
          -  Within 3 hours of injury (do not include if interval cannot be estimated e.g. patient&#xD;
             unable to confirm time of fall or patient found on floor after an unwitnessed fall and&#xD;
             home alone)&#xD;
&#xD;
          -  Not living in a nursing home, mental health institution or prison&#xD;
&#xD;
          -  Patient will be conveyed to or is admitted to a participating hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - TXA not clearly indicated (e.g. major bleeding) or contraindicated (e.g. suspected&#xD;
        stroke)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur-Still</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Roberts</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haleema Shakur-Still</last_name>
    <phone>+4407714139500</phone>
    <email>Haleema.Shakur@lshtm.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben Bloom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Jarman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://crash4.lshtm.ac.uk</url>
    <description>Trial website</description>
  </link>
  <link>
    <url>http://txacentral.lshtm.ac.uk</url>
    <description>TXA background information</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Traumatic brain injury, tranexamic acid, older adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared publicly when all planned analyses are completed by the CRASH-4 Trial Collaborators. This will be hosted on freebird.lshtm.ac.uk</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_access_criteria>Totally anonymised data (without random allocation, patient, country and site identifiers) will be freely available.Where random allocation codes, country/site identifiers are requested, appropriate pre-specified analysis plan will need to be submitted to the Trial Management Group for review and if necessary, appropriate Ethics Committee approval will be required.</ipd_access_criteria>
    <ipd_url>http://freebird.lshtm.ac.uk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

